020 7713 0990

This guideline is written to assist in the management if adult patients with chronic lymphocytic leukaemia (CLL). The guideline covers diagnostic testing, prognostication, first line management and management of relapsed disease including indications for allogeneic haematopoietic stem cell transplantation. Supportive care for patients with CLL is discussed along with specific consideration of the management of autoimmune sequelae.

Note: there is an error on page 16 of the published version: the dose of Intravenous immunoglobulin used to treat ITP should read 0.4g/kg/d not 0.4mg/kg/d.

An Interim statement regarding this guideline was produced in 2015. Please see the update below for more information.

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.